Nadia Daizadeh

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi et al. · The Lancet Diabetes & Endocrinology · 2017 · 961 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Bente Langdahl, Cesar Libanati, Daria B. Crittenden et al. · The Lancet · 2017 · 467 citations

Medicine, Endocrinology, Pharmacotherapy +14

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Socrates E. Papapoulos, Roland Chapurlat, Cesar Libanati et al. · Journal of Bone and Mineral Research · 2011 · 344 citations · Full text

Medicine, Orthopaedic Surgery, Bone Metabolism +14

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Socrates E. Papapoulos, Kurt Lippuner, Christian Roux et al. · Osteoporosis International · 2015 · 277 citations · Full text

Medicine, Endocrinology, Bone Metabolism +16

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

Henry G. Bone, Roland Chapurlat, Maria Luisa Brandi et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 252 citations · Full text

Medicine, Orthopaedic Surgery, Bone Metabolism +16